We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Joan Palou

Joan Palou MD, PhD, FEBU, FRCS (Glas)

Chairman, Department of Urology, Fundació Puigvert; Professor, Universitat Autònoma de Barcelona, Barcelona, Spain
Juan Palou Redorta, Prof, MD, PhD, is a world-renowned expert in bladder cancer and in Uro-oncology. He graduated at the Medical School of the Universitat Autònoma de Barcelona and became an urologist at the Hospital Vall d’Hebrón in Barcelona. He also spent some short periods in different centers in the USA during his residency training. He is Professor of Urology at the Universitat Autònoma de Barcelona (Spain) and Chairman of the Urology Department at the famous Fundació Puigvert in Barcelona. Prof. Palou is Chairman of the European School of Urology. In 2016 he became member of the American Association of Genito-Urinary Surgeons (AAGUS). He is, among many others, member of the Spanish Urological Association, European Association of Urology (EAU), American Urological Association and Société International d’Urologie. Prof. Palou is an expert in laparoscopy and robotic surgery belonging to a cooperative group in robotic radical cystectomy. He has collaborated with the International Consultation on Bladder Cancer, Upper tract and Penile Cancer, sponsored by the WHO and SIU. Most importantly, he has been involved in writing the EAU Guidelines for non-muscle invasive bladder cancer and upper urinary tract tumours. Prof. Palou has published many chapters in medical and urology books and more than 200 publications in peer-reviewed journals. His recent publications focus mainly on bladder cancer studying the different aspects such as prognostic factors, BCG, T1G2 tumors, T1G3 tumors, guidelines, risk stratification or robotic surgery. Some new protein markers of aggressiveness and prognosis of progression in patients with T1G3 tumours of the bladder has been developed with the CNIO (National Center for Oncologic Investigations), Columbia University and with other European centers with encouraging results. He is also a referee of several national and international journals. He has given countless lectures in national and international meetings and as a visiting professor in University Hospitals all over the world. His group has received several awards for publications, videos, oral and poster presentations at different meetings. The most known is the Hans Marberger prize in 2004.

Disclosures

Dr. Palou reports the following:
  • Trial participation: Cepheid, Presurgy, Ipsen, Combat, Storz, Archer, IDL Biotech, Palex
  • Honoraria/Consultant fees: Combat BRS, Olympus, Sanofi, Cepheid, Ipsen, Fidia Farmaceutici,
  • Advisory/Scientific Board: Pfizer, Astra Zeneca, Merck, Janssen, Ferring